drugset / Trial / NCT04662099
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
Phase 1
Unknown
24 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan Sian Medical Technology Co., Ltd · collab
NaSequentialOpen-labelTreatment
Summary
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2020-03-25
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
Publications
- Background Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020 May 8;11(1):2283. doi: 10.1038/s41467-020-16160-5.
- Background Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021 Feb;18(2):71-84. doi: 10.1038/s41571-020-0427-6. Epub 2020 Sep 25.
- Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, Zhang Y, Wang X, Wu Z, Kang Y, Zheng J, Xiong W, Deng J, Hu Y, Mei H. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024 Jan;38(1):149-159. doi: 10.1038/s41375-023-02065-x. Epub 2023 Oct 17.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS1-BCMA CAR-T cells | Cell therapy | 750000 cells/kg | — |
| Subject | CS1-BCMA CAR-T cells | Cell therapy | 3e+06 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |